204 related articles for article (PubMed ID: 10529385)
1. Cloning and characterization of a novel p21(Cip1/Waf1)-interacting zinc finger protein, ciz1.
Mitsui K; Matsumoto A; Ohtsuka S; Ohtsubo M; Yoshimura A
Biochem Biophys Res Commun; 1999 Oct; 264(2):457-64. PubMed ID: 10529385
[TBL] [Abstract][Full Text] [Related]
2. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation.
Asada M; Yamada T; Ichijo H; Delia D; Miyazono K; Fukumuro K; Mizutani S
EMBO J; 1999 Mar; 18(5):1223-34. PubMed ID: 10064589
[TBL] [Abstract][Full Text] [Related]
4. Ciz1, a p21 cip1/Waf1-interacting zinc finger protein and DNA replication factor, is a novel molecular partner for human enhancer of rudimentary homolog.
Lukasik A; Uniewicz KA; Kulis M; Kozlowski P
FEBS J; 2008 Jan; 275(2):332-40. PubMed ID: 18081865
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
Oncogene; 1999 May; 18(21):3290-302. PubMed ID: 10359535
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
Park US; Park SK; Lee YI; Park JG; Lee YI
Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
[TBL] [Abstract][Full Text] [Related]
7. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition by the muscarinic M(3) acetylcholine receptor: evidence for p21(Cip1/Waf1) involvement in G(1) arrest.
Burdon D; Patel R; Challiss RA; Blank JL
Biochem J; 2002 Oct; 367(Pt 2):549-59. PubMed ID: 12126481
[TBL] [Abstract][Full Text] [Related]
9. Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells.
Poon RY; Hunter T
Oncogene; 1998 Mar; 16(10):1333-43. PubMed ID: 9546435
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
Oncogene; 1999 Jul; 18(30):4313-25. PubMed ID: 10439039
[TBL] [Abstract][Full Text] [Related]
11. Hyperoxia induces S-phase cell-cycle arrest and p21(Cip1/Waf1)-independent Cdk2 inhibition in human carcinoma T47D-H3 cells.
Bilodeau JF; Faure R; Piedboeuf B; Mirault ME
Exp Cell Res; 2000 May; 256(2):347-57. PubMed ID: 10772807
[TBL] [Abstract][Full Text] [Related]
12. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells.
Lu Y; Yamagishi N; Yagi T; Takebe H
Oncogene; 1998 Feb; 16(6):705-12. PubMed ID: 9488034
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
Gong J; Ammanamanchi S; Ko TC; Brattain MG
Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
[TBL] [Abstract][Full Text] [Related]
14. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
[TBL] [Abstract][Full Text] [Related]
15. Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction.
Prabhu NS; Blagosklonny MV; Zeng YX; Wu GS; Waldman T; El-Deiry WS
Clin Cancer Res; 1996 Jul; 2(7):1221-9. PubMed ID: 9816291
[TBL] [Abstract][Full Text] [Related]
16. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase.
Ono T; Kitaura H; Ugai H; Murata T; Yokoyama KK; Iguchi-Ariga SM; Ariga H
J Biol Chem; 2000 Oct; 275(40):31145-54. PubMed ID: 10878006
[TBL] [Abstract][Full Text] [Related]
17. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells.
Sekiguchi T; Hunter T
Oncogene; 1998 Jan; 16(3):369-80. PubMed ID: 9467962
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
19. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity.
Kriwacki RW; Hengst L; Tennant L; Reed SI; Wright PE
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11504-9. PubMed ID: 8876165
[TBL] [Abstract][Full Text] [Related]
20. v-Jun stimulates both cdk2 kinase activity and G1/S progression via transcriptional repression of p21 CIP1.
Maclaren A; Clark W; Black EJ; Gregory D; Fujii H; Gillespie DA
Oncogene; 2003 Apr; 22(16):2383-95. PubMed ID: 12717415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
